As new techniques of transferring from liquid to gas phase and measuring masses of drug molecules and metabolites become more prevalent, so do the technical challenges of putting these techniques into proper use, as well as the task of consolidating emerging applications. Identification and Quantification of Drugs, Metabolites and Metabolizing Enzymes by LC-MS, Volume 6 fills the gap in the lack of presently available literature by providing a critical review in the current use of liquid chromatography-mass spectrometry (LC-MS) in drug discovery and development. With chapters written by experts with a wide range of practical experience from the pharmaceutical industry, emphasis is placed on techniques and applications. The book also includes chapters on how to utilize LC-MS instrumentation for current drug metabolism problems. This book is intended for those beginning to use LC-MS for drug metabolism studies as well as for those considered advanced practitioners. Biografía del autor Dr. Chowdhury is currently a Director of DMPK at Takeda Pharmaceutical International Co. in Cambridge, MA, responsible for evaluating metabolism, toxicity, and potential for drug-drug interaction due to modulation of activities of metabolizing enzymes and transporters by compounds in discovery and development. Dr. Chowdhury obtained his Ph.D. from the University of Alberta in 1987. After spending a year and a half as a post-doctoral fellow at the University of Toronto, Dr. Chowdhury joined Rockefeller University as a Research Associate in the laboratory of Professor Brian Chait. At Rockefeller University, Dr. Chowdhury was involved in the early stage of the development of atmospheric pressure ionization (API) mass spectrometry. This early research on API led to the introduction of a novel API system for LC/MS. After leaving Rockefeller University, he worked on the applications of liquid chromatography/mass spectrometry techniques at several non-academic organizations, including at Schering-Plough Research Institute (SPRI), where he worked for fifteen years in the Department of Drug Metabolism and Pharmacokinetics. The focus of his research at SPRI was to investigate the biotransformation of drugs in support of drug discovery and development. He was involved with the development and registration of a number of pharmaceuticals including Temodar, Clarinex, Zetia, Noxafil, Nasonex/Asmanex, and Victrelis. Dr. Chowdhury is an author of nearly 100 original publications covering a broad area of drug metabolism and drug-drug interaction and analytical technologies to evaluate them.
- Libro Impreso
- Edición:
- Editorial: Vintage
- Autor: Chowdhury, Swapan
